Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Liver transplantation].

J I Herrero1, F Pardo, J Quiroga

  • 1Unidad de Hepatología, Clínica Universitaria de Navarra, Pamplona, 31008, Spain. iherrero@unav.es

Anales Del Sistema Sanitario De Navarra
|September 26, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

β-Hydroxybutyrate impairs the functional response of bovine neutrophils to mammary pathogenic Staphylococcus aureus and a TLR2/1 agonist by limiting glucose metabolism.

Journal of dairy science·2026
Same author

Assessment of microplastic retention efficiency using pilot-scale filtration systems applied to drinking water.

Journal of hazardous materials·2025
Same author

Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial.

ESMO open·2025
Same author

Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer.

ESMO open·2025
Same author

Impact of pregestational obesity on perinatal complications: update in a Latin American cohort.

Public health·2024
Same author

Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer.

ESMO open·2024
Same journal

[Subacute meningoencephalitis following intravesical BCG instillation immunotherapy].

Anales del sistema sanitario de Navarra·2026
Same journal

[Treatment with dabrafenib and trametinib in an intrahepatic cholangiocarcinoma harboring a BRAF V600E mutation].

Anales del sistema sanitario de Navarra·2026
Same journal

[Efficiency after integrating a hospital with a 'new management model'].

Anales del sistema sanitario de Navarra·2026
Same journal

[Anales del Sistema Sanitario de Navarra in 2025: Progress continues].

Anales del sistema sanitario de Navarra·2026
Same journal

Qualitative evaluation of a community intervention in educational centres: Opinion of the professionals involved.

Anales del sistema sanitario de Navarra·2026
Same journal

[Unequal impact of COVID-19 on mortality in long-term care homes across health areas of Castilla-La Mancha (Spain)].

Anales del sistema sanitario de Navarra·2026
See all related articles

Liver transplantation offers an effective treatment for end-stage liver disease, with improved survival rates. Advances in techniques and reduced contraindications enhance outcomes for patients with cirrhosis, tumors, or acute liver failure.

Area of Science:

  • Hepatology
  • Transplant Surgery

Background:

  • Liver transplantation is a key treatment for end-stage liver disease.
  • Primary indications include hepatic cirrhosis, tumors (hepatocellular carcinoma), and acute liver failure.

Purpose of the Study:

  • To review the efficacy and outcomes of liver transplantation.
  • To highlight advancements in surgical techniques and eligibility criteria.

Main Methods:

  • Review of current literature on liver transplantation.
  • Analysis of survival data and transplant indications.

Main Results:

  • Liver transplant survival rates are approximately 90% at one year and 80% at five years.
  • Absolute contraindications for transplantation have decreased over time.

Related Experiment Videos

  • Surgical techniques have evolved, improving transplant success.

    • Conclusions:

    • Liver transplantation is a highly effective therapy for terminal hepatic diseases.
    • Ongoing advancements continue to improve patient survival and broaden eligibility.